We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Study of a New Dressing for Use With Topical Medications

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00234728
Recruitment Status : Completed
First Posted : October 7, 2005
Last Update Posted : July 2, 2008
Information provided by:
Teikoku Pharma USA, Inc.

Brief Summary:
The purpose of this study is to determine if a new dressing designed to be used with topical medications will enhance the effects of these topical medications.

Condition or disease Intervention/treatment Phase
Psoriasis Device: Occlusive dressing Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Bilaterally-Controlled Single Center Study to Compare the Efficacy of Occlusion of Topical Agents With a Hydrophilic Occlusive Dressing to Treatment With Occlusive Dressing Without the Addition of Topical Agents
Study Start Date : September 2005
Actual Study Completion Date : June 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Primary Outcome Measures :
  1. Efficacy of topical medications with new occlusive dressing at baseline, weeks 2, 4, 6, 8.

Secondary Outcome Measures :
  1. Efficacy with new occlusive dressing alone without topical medications at baseline, weeks 2, 4, 6, 8.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subject has signed the informed consent form and HIPAA authorization form
  • Male or female subject at least 18 years of age
  • A diagnosis of stable plaque-type psoriasis vulgaris with at least one "mirror image" pair of symmetric lesions on either the trunk, arms, or legs that would serve as target lesions. Paired target lesions must be in similar anatomic locations (e.g., right and left elbows or right and left knees) and have roughly equal (no more than one point difference) modified PASI scores. Both paired target lesions must have PASI scores equal to or greater than 1.5
  • Any additional diagnoses must, in the investigator's opinion, not preclude the subject from safely participating in this study or interfere with the evaluation of the subject's psoriasis
  • Psoriasis must be clinically stable for at least 30 days before enrollment
  • Subject is able to completely discontinue the use of any medication or therapy for relief of psoriasis in the target areas to be treated
  • Subject is able to completely discontinue the use of any systemic medication or therapy (e.g. oral or injectable psoriasis medications, PUVA phototherapy, herbal remedies, or acupuncture) for relief of psoriasis
  • Female subjects must be postmenopausal (defined as one year without menses), physically incapable of becoming pregnant, or using an acceptable birth control method. Acceptable methods of birth control include hormonal contraceptives or double-barrier methods (condom, diaphragm with spermicidal agent or IUD). If practicing an acceptable method of birth control, the subject must have confirmation of a negative urine pregnancy test at Screening
  • Subject must be reliable and mentally competent to complete study measurements
  • Subject is able to understand and agrees to comply with study requirements, attend study visits, and comply with the restrictions during the study.

Exclusion Criteria:

  • Subject has a skin disorder other than psoriasis in the target areas to be evaluated
  • Known hypersensitivity to any component of the test medications
  • Pigmentation, extensive scarring, or pigmented lesions in affected areas that would interfere with evaluation of efficacy parameters
  • Clinically infected psoriasis at baseline
  • Subject is pregnant or nursing
  • Guttate, pustular, erythrodermic, or other non-plaque forms of psoriasis
  • Spontaneously worsening or improving psoriasis within 30 days of enrollment
  • Any evidence of atrophy in the areas selected for treatment with topical corticosteroid
  • History of treating potential target lesions differently from one another
  • Topical or intralesional therapies (other than emollients) or UVB phototherapy on potential target lesions within two weeks of starting study treatment
  • Systemic therapy, PUVA phototherapy, or a systemic investigational therapy for psoriasis within 30 days prior to study entry
  • Treatment with topical investigational therapy of the target lesions within 30 days prior to study entry
  • Subject is considered unreliable as to medication compliance or adherence to scheduled appointments as determined by the investigators.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00234728

Layout table for location information
United States, California
UCSF Psoriasis and Skin Treatment Center
San Francisco, California, United States, 94118
Sponsors and Collaborators
Teikoku Pharma USA, Inc.
Layout table for investigator information
Principal Investigator: John Koo, MD University of California, San Francisco
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00234728    
Other Study ID Numbers: TPU-2005-02
First Posted: October 7, 2005    Key Record Dates
Last Update Posted: July 2, 2008
Last Verified: June 2008
Keywords provided by Teikoku Pharma USA, Inc.:
occlusive dressing
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases